(NYSE: MRK) Merck &'s forecast annual revenue growth rate of 4.63% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.
Merck &'s revenue in 2020 is $47,348,000,000.On average, 4 Wall Street analysts forecast MRK's revenue for 2021 to be $130,621,086,930,687, with the lowest MRK revenue forecast at $126,100,372,026,990, and the highest MRK revenue forecast at $135,016,376,769,722. On average, 4 Wall Street analysts forecast MRK's revenue for 2022 to be $137,229,025,147,267, with the lowest MRK revenue forecast at $125,849,977,161,060, and the highest MRK revenue forecast at $145,109,237,382,325.
In 2023, MRK is forecast to generate $134,512,627,825,810 in revenue, with the lowest revenue forecast at $129,345,388,319,800 and the highest revenue forecast at $139,679,867,331,820.